Developer docs
API playgroundTry for free, no card

Search company profiles

Wellmarker Bio

Full company profile

uuid000379j

Namestring
Wellmarker Bio
Legal namestring
Wellmarker Bio
Websiteurl
wmbio.co
Company typeenum
Private
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
anticancer drug development, oncology therapeutics, clinical trials, biotech research, drug discovery
Industry4 codes
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Technology Exports
TypeLicensing Royalties
Description

The company is engaging in technology exports as part of its revenue strategy, indicating a technology licensing model for its drug development intellectual property.

mk.co.kr
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Wellmarker Bio is a South Korean biotech company that develops novel anticancer drugs. The company conducts clinical trials for its therapeutic candidates (including trials run in Australia), plans preclinical and Investigational New Drug (IND) submissions for new drug candidates, and engages in technology exports and licensing of its drug development intellectual property to pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successfully completed Series C funding round raising approximately 14 billion won
+1 more record
Product and service1 record
1Anticancer Drug Development Program
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wellmarker Bio

Oncology Therapeuticswmbio.co

Wellmarker Bio firmographics

Firmographics
Name
Wellmarker Bio
Legal name
Wellmarker Bio
Website
https://wmbio.co
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Wellmarker Bio industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Anticancer drug development
  • Oncology therapeutics
  • Clinical trials
  • Biotech research
  • Drug discovery

Where Wellmarker Bio is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Markets served

Wellmarker Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Technology Exports: The company is engaging in technology exports as part of its revenue strategy, indicating a technology licensing model for its drug development intellectual property.

Go-to-market motion1 record

Wellmarker Bio product offering

Product offering

Core offering

Wellmarker Bio is a South Korean biotech company that develops novel anticancer drugs. The company conducts clinical trials for its therapeutic candidates (including trials run in Australia), plans preclinical and Investigational New Drug (IND) submissions for new drug candidates, and engages in technology exports and licensing of its drug development intellectual property to pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Products and services

  • Anticancer Drug Development Program

Quantifiable outcome

  • Successfully completed Series C funding round raising approximately 14 billion won
  • +1 more outcomes

Companies that use Wellmarker Bio

Customer profile

Segments1 record

Ideal customer profiles2 records

Wellmarker Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Wellmarker Bio partnerships and signals

Strategic signal

Scale indicators1 record

Wellmarker Bio competitors and assessment

Company assessment

Market position

Customer concentration

Wellmarker Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wellmarker Bio leadership team

Management profile

Number of profiles

Profiles1 record

Wellmarker Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wellmarker Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellmarker Bio

What does Wellmarker Bio do?

Wellmarker Bio is a South Korean biotech company that develops novel anticancer drugs. The company conducts clinical trials for its therapeutic candidates (including trials run in Australia), plans preclinical and Investigational New Drug (IND) submissions for new drug candidates, and engages in technology exports and licensing of its drug development intellectual property to pharmaceutical partners.

Is Wellmarker Bio a public or private company?

Wellmarker Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Wellmarker Bio founded?

Wellmarker Bio was founded in 2016. It employs 1 to 10 people.

Where is Wellmarker Bio based?

Wellmarker Bio is headquartered in Seoul, South Korea, in the Asia region.

How does Wellmarker Bio make money?

One revenue line is on record: technology Exports.

Does Wellmarker Bio have an API?

No public API is recorded for Wellmarker Bio.

What industry is Wellmarker Bio in?

Wellmarker Bio's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAF, Translational Medicine & Biomarkers, with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWellmarker Bio Announces Clinical Trial Collaboration with MSD to evaluate WM-A1-3389 in combination with KEYTRUDA® (pembrolizumab)Wellmarker Bio Co., Ltd entered into a clinical trial collaboration and supply agreement with MSD (Merck & Co., Inc.) on February 7, 2023, to evaluate WM-A1-3389, a novel therapeutic antibody targeting a new immune checkpoint protein, in combination with KEYTRUDA (pembrolizumab) for Non-Small Cell Lung Cancer patients with low or no PD-L1 expression. Under the agreement, Wellmarker Bio will sponsor Phase 1 trials for the treatment, which addresses a high unmet medical need as these patients have shown limited response to immunotherapy alone. The company is also planning to expand the target patient group to other solid tumor indications.MkWellmarker Bio, Series C investment attraction and acquisition of the Ministry of SMEs and Startups' Inno-Biz certificationWellmarker Bio announced it received an A-grade evaluation from the Ministry of SMEs and Startups and was designated an excellent corporate research institute by the Ministry of Science and Technology. The company raised about 14 billion won in Series C funding at the end of August, with Cytogen as a strategic investor. It is running a Phase 1 trial of WM-S1-030 on over 100 patients in Australia.PR NewswireWellmarkerBio reçoit l'approbation de la Therapeutic Goods Administration australienne pour un essai clinique de phase IWellmarker Bio, a South Korean biotech company, received approval from Australia's Therapeutic Goods Administration on February 23, 2021, to conduct a Phase I clinical trial for WM-S1-030, a targeted cancer drug for colorectal cancer and progressive tumors. The trial will enroll 100 advanced cancer patients across multiple Australian sites, including Linear Clinical Center and Monash Hospital, in two phases testing dose escalation and combination therapies. WM-S1-030 demonstrated significant tumor growth inhibition in colorectal cancer models resistant to Erbitux (cetuximab), positioning it as a potential first-in-class treatment for patients with unmet medical needs.PR NewswireWellmarkerBio recibe la aprobación del ensayo clínico de Fase 1 de la TGAWellmarker Bio, a South Korean biotech company headquartered in Seoul, received approval from the Australian Therapeutic Goods Administration on February 23, 2021, to conduct a Phase 1 clinical trial for its anticancer drug candidate WM-S1-030, which targets colorectal cancer and progressive cancers. The trial will enroll 100 advanced cancer patients across Australian sites including the Linear Clinical Center and Monash Hospital, proceeding through dose escalation and dose expansion phases. WM-S1-030 has demonstrated significant tumor growth inhibition in colorectal cancer models resistant to Erbitux (cetuximab), positioning it as a potential first-in-class therapy for patients with KRAS wild-type and mutant genotypes who lack alternative treatment options.PR NewswireWellmarker Bio erhält Zulassung für klinische Phase-I-Studie von der Australian Therapeutic Goods AdministrationWellmarker Bio announced on February 23, 2021, that it received approval from Australia's Therapeutic Goods Administration (TGA) to conduct a Phase I clinical trial for WM-S1-030, a targeted cancer drug for treating colorectal and advanced-stage cancer. The trial will recruit 100 patients across multiple Australian centers including Linear Clinical Center and Monash Hospital, progressing through Phase Ia (dose escalation) and Phase Ib (dose expansion). WM-S1-030 has demonstrated significant tumor growth suppression in Erbitux-resistant colorectal cancer models and could be positioned as a first-in-class drug for patients with no alternative treatment options.